Conference Coverage
Conference Coverage
09/27/2024
Anthony Calabro, MA
Researchers who developed a meta-analysis of 19 randomized controlled trials found a statistically significant improvement in overall survival with sorafenib when compared with placebo for patients with...
09/27/2024
FDA Alert
FDA Alert
04/22/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA previously approved lisocabtagene maraleucel as a second-line treatment option for adult patients with large B-cell lymphoma in June 2022.
04/22/2024
Conference Coverage
Conference Coverage
03/13/2024

Anthony Calabro, MA

Anthony Calabro, MA
The study findings potentially challenge the conventional wisdom that the risk of Richter transformation would increase as patients with chronic lymphocytic leukemia live longer with novel treatments. This...
03/13/2024
Conference Coverage
Conference Coverage
02/23/2024

Anthony Calabro, MA

Anthony Calabro, MA
Researchers assessed the efficacy of venetoclax-based treatments for patients with relapsed/refractory chronic lymphocytic leukemia. This study was presented at the 65th ASH Annual Meeting & Exposition...
02/23/2024
Conference Coverage
Conference Coverage
01/31/2024

Anthony Calabro, MA

Anthony Calabro, MA
Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
01/31/2024
Research Summary
Research Summary
01/29/2024

Anthony Calabro, MA

Anthony Calabro, MA
A recent phase 3 trial showed that for untreated patients with chronic lymphocytic leukemia, measurable residual disease-directed ibrutinib–venetoclax therapy had superior progression-free survival compared...
01/29/2024
Conference Coverage
Conference Coverage
12/12/2023

Anthony Calabro, MA

Anthony Calabro, MA
In their case-controlled study that utilized the National Inpatient Sample 2016-2019 database, researchers set out to examine the relationship between leukemia and sickle cell trait.
12/12/2023
Research Summary
Research Summary
10/26/2023

Anthony Calabro, MA

Anthony Calabro, MA
Researchers set out to determine the impact of midostaurin in adult patients with FLT3-mutated acute myeloid leukemia.
10/26/2023
Research Summary
Research Summary
09/20/2023

Anthony Calabro, MA

Anthony Calabro, MA
Researchers performed a retrospective observational study to determine whether DNA sequencing can detect residual disease in adults with acute myeloid leukemia (AML) in first remission.
09/20/2023
Conference Coverage
Conference Coverage
09/08/2023

Anthony Calabro, MA

Anthony Calabro, MA
Researchers reported on the treatment approaches and outcomes of patients with T‑cell prolymphocytic leukemia after allogeneic transplant in a multicenter, retrospective study.
09/08/2023